Since nirsevimab is specific for RSV without any endogenous targets, AESIs comprised risks common to any exogenous immunoglobulin, including hypersensitivity reactions and immune complex disease [27], which could potentially be triggered by ADAs. The gene discussed is AGPS; the disease is type III hypersensitivity disease.